PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of molcancBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleMolecular CancerJournal Front Page
 
Mol Cancer. 2010; 9: 103.
Published online 2010 May 10. doi:  10.1186/1476-4598-9-103
PMCID: PMC2881116

Cyclin K and cyclin D1b are oncogenic in myeloma cells

Abstract

Background

Aberrant expression of cyclin D1 is a common feature in multiple myeloma (MM) and always associated with mantle cell lymphoma (MCL). CCND1 gene is alternatively spliced to produce two cyclin D1 mRNA isoforms which are translated in two proteins: cyclin D1a and cyclin D1b. Both isoforms are present in MM cell lines and primary cells but their relative role in the tumorigenic process is still elusive.

Results

To test the tumorigenic potential of cyclin D1b in vivo, we generated cell clones derived from the non-CCND1 expressing MM LP-1 cell line, synthesizing either cyclin D1b or cyclin K, a structural homolog and viral oncogenic form of cyclin D1a. Immunocompromised mice injected s.c. with LP-1K or LP-1D1b cells develop tumors at the site of injection. Genome-wide analysis of LP-1-derived cells indicated that several cellular processes were altered by cyclin D1b and/or cyclin K expression such as cell metabolism, signal transduction, regulation of transcription and translation. Importantly, cyclin K and cyclin D1b have no major action on cell cycle or apoptosis regulatory genes. Moreover, they impact differently cell functions. Cyclin K-expressing cells have lost their migration properties and display enhanced clonogenic capacities. Cyclin D1b promotes tumorigenesis through the stimulation of angiogenesis.

Conclusions

Our study indicates that cyclin D1b participates into MM pathogenesis via previously unrevealed actions.

Background

Cyclin D1 is a key actor for the development and progression of various cancers including hematological malignancies. The human CCND1 gene generates two mRNA species by alternative splicing [1]. The two corresponding proteins cyclin D1a and D1b differ only in the last 55 amino acids of the carboxy-terminus. Both isoforms possess the N-terminal domain, necessary for retinoblastoma protein (pRb) binding, the cyclin box, required for cyclin-dependent kinase (CDK) binding and activation and the central region, implicated in transcriptional regulation. The PEST sequence which controls protein turn-over and the threonine 286 (Thr286), the site of phosphorylation by glycogen synthase kinase-3β which promotes the nuclear export of cyclin D1 and its degradation through the proteasome pathway [2,3], are present only in cyclin D1a. The oncogenic potential of cyclin D1 seems restricted to the isoform b as shown in vitro [4-6]. In transgenic mouse models, inhibition of cyclin D1 proteolysis is the causative factor for mammary carcinomas and B-cell lymphomas [7,8]. The mechanisms of cyclin D1b-mediated tumorigenesis are not fully understood and could depend on the cellular context and in particular on the concomitant expression of cyclin D1a.

Cyclin K is encoded by Kaposi sarcoma-associated herpes virus (KSHV), a human tumor virus associated with the development of Kaposi sarcoma and lymphoid malignancies in immunocompromised individuals, reviewed in [9]. Cyclin K and cyclin D1 share sequence colinearity and identity. The tumorigenic properties of cyclin K have been demonstrated in transgenic animals in which the lymphocyte compartment has been targeted [10]. In a similar transgenic model, cyclin D1a alone fails to induce leukemogenesis [11,12].

Mantle cell lymphoma (MCL) and multiple myeloma (MM) are two hematological malignancies for which cyclin D1 expression has been recognized as an oncogenic event [13,14]. Although cyclin D1a and D1b mRNAs are present in all MCL and MM samples tested, cyclin D1a protein is expressed predominantly [15,16]. However, a role of cyclin D1b in the leukemogenic process cannot be ruled out. In order to study the oncogenic potential of cyclins D1b and K in the context of mature B cells, we generated several cell clones derived from LP-1 MM cell line, expressing either cyclin D1b, Myc or cyclin K oncogenes. LP-1 cell line was chosen because this MM cell line does not express any cyclin D1 isoform. We report here that cyclin D1b- and cyclin K-expressing LP-1 cells are tumorigenic in vivo in xenograft models. Genome-wide analysis allowed us to describe several mechanisms for cyclin D1b- and K-mediated oncogenesis.

Methods

Generation of LP-1-derived clones

LP-1 MM cell line which does not express cyclin D1 was chosen for the generation of stable transfected clones. GRANTA-519 MCL cell line has the t(11;14)(q13;q32) and expresses high level of cyclin D1a. LP-1 and GRANTA-519 cells were maintained in RPMI 1640 containing 10% fetal calf serum (FCS), L-glutamine and antibiotics (Lonza Verviers SPRL, Verviers, Belgium). pcDNA3-flagged cyclin K [17] (a generous gift of O. Coqueret), pcDNA3-c-Myc (a generous gift of D. Cappellen) and pcDNA3-cyclin D1b [18] encode for the full-length proteins, respectively. LP-1 cells were transfected by electroporation, selected with 500 μg/ml G418, cloned by limiting dilution in 96-well plates. Single clones were individually tested for exogenous protein expression. After three months in culture without loss of transgene expression, G418 was first reduced and finally removed.

Cell cycle analysis by flow cytometry

Exponentially growing LP-1-derived cells were plated at a density of 5 × 105 cells/ml, harvested 24 h later, fixed in ice-cold EtOH 80% in PBS. Cells were treated with 100 μg/ml RNase A and 20 μg/ml propidium iodide (PI) for 30 min at 37°C. Cells were analyzed with an Epics XL flow cytometer and data with the Expo™ 32 software (Beckman Coulter, Villepinte, France).

Matrigel invasion assay

LP-1-derived cells were suspended in FCS-free RPMI 1640 medium and 2 × 104 cells were placed in the upper chamber of transwell inserts coated with Matrigel (BD BioCoat Matrigel Invasion Chamber, BD Biosciences, Le Pont de Claix, France). In the lower compartment, we added RPMI 1640 medium plus 1% FCS. Plates were incubated for 4 h at 37°C to allow migration of cells. After incubation, inserts were carefully removed, washed, fixed and colored to allow cell counting. Results are expressed as the number of cells that invaded the Matrigel. Statistical analysis between two groups was done with the Student's t test.

Clonogenicity assay

The ability of individual cell to grow in semi-solid support was assayed using MethoCult® (StemCell Technologies, Grenoble, France) according to the manufacturer' instructions. Cells were prepared at a density of 3 × 103 cells/ml in Iscove's MDM plus 2% FCS; then added to the same volume (3 ml) of methyl cellulose containing phytohemagglutin-leucocyte conditioned medium (PHA-LCM) as source of growth factor. Cells were dispensed in triplicate in Petri dishes, incubated in humidified atmosphere at 37°C for 10 days. Colonies containing more than 50 cells were counted using inverted microscope and gridded scoring dish.

Immunoblotting

Methods for protein extraction, SDS-PAGE and immunoblotting were described previously [18].

In vivo engraftment experiments

Female, six week-old nude mice (NMRI, Janvier, Le Genest Saint-Isle, France), were inoculated s.c. with 2.5 × 106 (1st set) or 4 × 106 (2nd set) cells of the various clones in Matrigel (BD Biosciences, v/v). Mice were regularly monitored for the development of palpable tumors. Tumor volumes based on caliper measurements were calculated by the ellipsoidal formula [1/2 (length2 × width)]. The first set of animals (five mice per clone) was sacrificed at eight weeks (see Figure Figure1b).1b). The second series of animals (ten animals per clone) was sacrificed depending on the tumor sizes (see Figure Figure2a).2a). Tumors were then either fixed in Finefix (Microm Microtech., Francheville, France) or frozen for further analyses. In a third series of experiment, the LP-1D1b clone (5 × 106 cells) was inoculated in Matrigel into the lower flank of nude mice. The day after, 10 μM of either scrambled siRNA (5'-aat tct ccg aac gtg cac gt-3') or siRNA targeting VEGF (5'-aag gag acc ctg atg aga tc-3') were mixed with AteloGene™ (Koken, Cosmo Bio Co., Tokyo, Japan) according to manufacturer's instructions. The mixture (150 μl) was s.c. injected wrapping up the cells at the injection site. Chemical tyrosine kinase (TK) inhibitors targeting VEGFR2/3 (SAR 131675.13, (SAR)) and all FGFR (SSR 128129E.13, (SSR)), a gift of F. Bono, were dissolved in 5% glucose in physiological serum. SAR and SSR were i.v. injected biweekly at 40 mg/kg each, starting at day 1 following inoculation of cells. Each group contained 5 mice. At day 11, volume of tumors was measured as before and the growth of tumors monitored thereafter. The tumor evolution was calculated as the ratio between the volume of tumors at each time point and the volume of the tumors of non treated mice at day 11. Statistical analysis for tumor evolution in each group was done with the Student's t test. During the experiments, mice had free access to food and water and all the experiments were performed at the Common Service of Animal Experimentation (UFR de Pharmacie, Châtenay-Malabry), in accordance to the declaration of Helsinki on animal welfare and with the approval of the ethics committee of the University of Paris 11/CNRS (responsible person V. Dommergue-Dupont).

Figure 1
Cyclin D1b and cyclin K are oncogenic in nude mice. a) Generation of LP-1-derived clones. Total proteins were extracted from individual clones, resolved by SDS-PAGE (12%) and immunoblotted with anti-cyclin D1 Ab which detects both cyclin D1a and b isoforms ...
Figure 2
The engrafment potential of LP-1K and LP-1D1b does not rely on exacerbated proliferation properties. a) In a second set of engraftment assay, mice were monitored for tumor appearance, and the volume of the tumor evaluated. In the histograms are indicated ...

Immunohistochemistry of tumor sections

Finefix-fixed paraffin embedded 4 μm-sections were deparaffinized in toluene twice for 5 min and rehydrated by using graded EtOH concentrations. After antigen retrieval in citrate buffer pH 6.2 (5 min, 85°C), immunohistochemical labeling with anti-CD138 or anti-CD34 antibodies (Abs) was performed with the Vector Vectastain Elite kit (Vector Laboratories, Burlingame, CA, USA) and 3',3' Diaminobenzidine (DAB) as chromogen. Sections were counterstained with hemalun.

Microarray hybridization, gene expression data and statistical analyses

For each cell line (LP-1cl1, LP-1K and LP-1D1b), total RNA was extracted from four independent cultures with Trizol reagent (Invitrogen, Cergy Pontoise, France) according to the manufacturer' instructions and used for expression analysis on a 25K human oligonucleotide microarray covering most of the known human transcripts. The 50 mers 5'-amino modified oligonucleotides from the RNG/MRC oligonucleotide collection [19] (information available at http://www.microarray.fr:8080/merge/index) were diluted to a final concentration of 50 mM in 50% dimethyl sulfoxide, 100 mM potassium phosphate (pH 8.0) and printed onto hydrogel-coated slides (Nexterion H slides, Schott, Jena, Germany) using a microGrid II arrayer (Genomic Solutions, Cambridge, UK). Total RNAs (200 ng) were amplified by linear PCR and labelled with Cy3 using Bioprime Array CGH Genomic Labelling System Kit (Invitrogen). Total RNA from one culture of LP-1cl1 cells was similarly amplified, labelled with Cy5 and used as a reference probe for hybridization. Each Cy3-labelled probe was co-hybridized with the Cy5 reference probe on microarrays in a G2545A oven (Agilent, Massy, France) at 60°C for 18 h. Microarrays were washed (10 min in 6× SSC, 0.005% Triton-X100; 5 min in 0.1× SSC, 0.0025% Triton-X100) and scanned with a G2565B scanner (Agilent). Raw data were extracted from scanned microarray images (.tif) using Feature Extraction Software v9.5 (Agilent) and normalized using the Quantile method adapted to bicolour microarrays. All the protocols used can be obtained by contacting the microarray and sequencing platform of the IGBMC (web site: http://www-microarrays.u-strasbg.fr/). In order to select genes that are differentially expressed among the three biological groups (LP-1cl1, LP-1K and LP-1D1b), we performed an analysis of variance using Cy5/Cy3 log2 ratios. To limit the error due to multiple tests, we used permutation of samples for controlling the false discovery rate [20]. Genes with a p-value less than 0.01 were considered to be significant. Moreover, we filtered out genes with a fold change (FC). The FC between LP-1K and LP-1cl1 was calculated as the median value of the 4 replicates ratios in the LP-1K samples over the median value of the 4 replicates ratios in the LP-1cl1 samples. Three FC were calculated: LP-1K vs. LP-1cl1, LP-1D1b vs. LP-1cl1 and LP-1K vs. LP-1D1b and a threshold equal to 2 was used for selecting three lists of significant genes. To design Venn diagram, we used the VENNY software http://bioinfogp.cnb.csic.es/tools/venny/ and individual gene expression profiles were generated with the TigrMev 4_03 software http://www.tm4.org/mev.html. To determine functional relationships between genes, we used DAVID Bioinformatics Resources http://david.niaid.nih.gov.

Real-time quantitative RT-PCR

To validate the microarray data, we used RNAs previously used for microarray hybridization. Primers for 36B4, CSN2, FGFR3, FHIT, HSP90B1, TUBB2B, TFRC, CD48, LTB, FN1, BCL2, CDK6, GAPDH and UCHL1 genes were designed with the LightCycler® Probe Design software (Roche Diagnostics, Meylan, France). Their sequences are reported in the Additional File 1, Table S1. Q-PCR was carried out in a LightCycler® system (Roche Diagnostics) using the LightCycler® FastStart DNA master SYBR Green I kit (Roche Diagnostics) according to the manufacturer's instructions. Cycles were as follows: a 10 min initial cycle at 95°C, followed by 45 cycles of 10 sec of denaturation at 95°C, 5 sec of annealing at 58°C, and 10 sec of extension at 72°C. The specificity of the fluorescence was verified by the melting curve analysis after each reaction. The relative abundance of each target was normalized to 36B4 expression and the quantification of each mRNA compared to 36B4 was done using the comparative threshold method (Ct).

Tumor engraftment onto chick chorio-allantoic membrane

Fertilized chicken eggs (EARL Morizeau, Dangers, France) were handled as described previously [21]. On embryonic day 10, a plastic ring was placed on chick chorio-allantoic membrane (CAM) and 107 LP-1K or LP-1D1b cells in 30 μl Matrigel (BD Biosciences) were deposited after gentle laceration of the surface. Digital pictures were taken under a stereomicroscope (Nikon SMZ1500) at day 2, 4, 6 of tumor development. Twenty eggs were used for each condition.

Results

Cyclin D1b, cyclin K and c-Myc expressing LP-1-derived clones display tumorigenic properties

Stable LP-1 clones were generated by transfection of cyclin D1b-, cyclin K- or c-Myc-expressing pcDNA3 plasmids or empty pcDNA3 as control. As shown Figure Figure1a,1a, in the two clones LP-1 D1b (1 and 2), the short isoform b of cyclin D1 was expressed (clone 1) or overexpressed (clone 2) at a level comparable to the one in GRANTA-519 MCL cell line which possesses the t(11;14)(q13;q32) and synthesizes high level of cyclin D1a. Endogenous c-Myc was present in the control LP-1 pcDNA3 clone 1, and exogenous c-Myc was overexpressed (×5) in the two LP-1 c-Myc-expressing clones. In the LP-1 CK clone, cyclin K was detected with the anti-Flag M2 Ab. A representative clone from each series (star in Figure Figure1a),1a), thereafter referred as LP-1cl1 (control), LP-1K, LP-1 Myc or LP-1D1b was injected s.c. into a first set of five nude mice. Eight weeks after injection, tumors were present at the site of inoculation in 4/5 mice for LP-1K, 5/5 mice for LP-1 Myc and 3/5 mice for LP-1D1b (Figure (Figure1b)1b) but not in mice inoculated with the control clone LP-1cl1. Only one mouse developed a palpable lump (pseudo-tumor, which regresses spontaneously). Macroscopically, tumors were distinguishable from one clone to the other, cyclin D1b-induced tumors being bigger and highly vascularized. After hematoxilin-eosin-safran (HES) staining of fixed tumor sections, histology revealed the presence of typical malignant plasma cells (Figure (Figure1b).1b). In a second series of in vivo experiments, 10 animals per cell line were inoculated. Four weeks after injection, tumors were detected at the site of inoculation in 10/10 mice for LP-1K and 6/10 mice for LP-1D1b (Figure (Figure2a).2a). Five mice from each series were sacrificed and the others monitored for four more weeks. At that time, four more mice in the LP-1D1b series bore tumors. The most striking differences between the two series were the size of the tumors (Figure (Figure2a)2a) and again the rich vascularization of LP-1D1b tumors (data not shown). Immunohistological examination of tumor sections indicated that engrafted tumors contained bona fide myeloma cells expressing CD138 (Figure (Figure2b).2b). Our data show unambiguously that such as c-Myc, cyclin D1b and cyclin K are capable to confer a malignant phenotype to LP-1 MM cells and are oncogenic in vivo.

Cyclin D1b and cyclin K are not mitogenic in LP-1 cells

We used flow cytometry sorting of PI-stained exponentially growing cells to assess the cell proliferation capacities of LP-1-derived clones. As presented in Figure Figure2c,2c, the overexpression of cyclin D1b, cyclin K or c-Myc did not enhance the percentage of cells within the S phase of the cell cycle. By contrast, both LP-1D1b and LP-1K exhibited spontaneous apoptosis. In LP-1K cells, we observed a concomitant decrease of DNA synthesizing cells. We concluded from these data that the oncogenic properties acquired by LP-1 cells do not rely on an exacerbated proliferation potential.

Cyclin D1b and cyclin K expression alter LP-1 cells transcriptome

We used transcriptome analysis to evaluate cyclin D1b- and cyclin K-induced changes in LP-1 cells. Microarray data and annotations have been deposed in the NIH gene expression Omnibus under accession number GSE15497. A Venn diagram was used to visualize the overlap between three data sets: LP-1K vs. LP-1cl1, LP-1D1b vs. LP-1cl1, LP-1K vs. LP-1D1b (FC>2, Figure Figure3a).3a). This diagram shows that the expression of cyclin K had major effects on LP-1 transcriptome (593+444+90+1628 sequences were modified); less sequences were altered by both cyclin D1b and cyclin K (444+90) or cyclin D1b alone (156+153). We then filtered sequences to select genes coding for proteins having known biological functions and FC>3 to limit the number of genes to study. The number of genes up- or down-regulated in LP-1K or/and LP-1D1b cells is indicated in Figure Figure3b.3b. Individual gene expression profiles were generated with the TigrMev 4_03 software (Additional File 2 Figure S1, Additional File 3 Figure S2 and Additional File 4 Figure S3). We then hierarchically clustered genes on the basis of their biological processes (Figure (Figure3c).3c). Numerous genes implicated in metabolism, signal transduction, transport, transcriptional and translational regulations were modified by cyclin K and/or cyclin D1b. Unexpectedly, genes regulating cell cycle, apoptosis, cell proliferation were less numerous. Genes involved in cell structure and cell motion were specifically modified by cyclin K, whereas genes regulating hematopoiesis were modified by cyclin D1b. Our data indicate that the transformation process elicited by cyclin D1b and cyclin K involved a broad range of cellular processes.

Figure 3
Transcriptome datasets. a) The Venn diagram drawn with VENNY software shows the overlaps between the sequences that are the most differentially expressed across the three transcriptome datasets (LP-1K vs. LP-1cl1, LP-1D1b vs. LP-1cl1 and LP-1K vs. LP-1D1b, ...

Cyclin D1b and cyclin K alter cell cycle and survival genes expression

Real-time RT-PCR was performed for validation of microarray results (Table (Table1).1). We found a good correlation between microarray and RT-PCR data for the altered expression of 7 genes in LP-1D1b and 6 genes in LP-1K. Western blots, flow cytometry (data not shown) and immunocytochemical assays further confirmed transcriptional data (Figure 4a, b). Among the genes encoding cell cycle-associated proteins altered in LP-1 derivatives (Table (Table22 and data not shown), we confirmed the downregulation of cyclin D2 in LP-1D1b cells (FC: -2.05), the downregulation of CDK2 in LP-1K cells (FC: -2.10), the complete disappearance of p18INK4C in LP-1K cells, a clear decrease of p53 level in LP-1K cells (Figure (Figure4a).4a). Although the level of transcription of the TP53 gene itself was not modified in LP-1K vs. LP-1cl1 cells, the transcription of two genes coding for two proteins involved in p53 stabilization were downregulated. These two proteins are the tumor protein p53 inducible protein 3 (TP53I3, FC: -3.57) and binding protein 2 (TP53BP2, FC: -2.12). CDKN2B mRNA was decreased both in LP-1K and LP-1D1b cells. However, at the protein level, no major differences were seen between LP-1cl1 and LP-1D1b whereas p15INK4B disappeared totally in LP-1K cells (Figure (Figure4a).4a). Differences of post-transcriptional mechanisms in each cell line could explain this variation between microarray and western blot data.

Table 1
Real-time quantitative RT-PCR for validation of microarray data
Figure 4
Cyclin K and cyclin D1b impact the biology of LP-1 cells. Proteins from exponentially growing cells were resolved by SDS-PAGE and immunoblotted with the following Abs: anti-cyclin D2 (sc-181), anti-CDK2 (sc-6248), anti-p15 (sc-612), anti-p18 (sc-865), ...
Table 2
Genes coding for cell cycle regulatory molecules displaying altered expression in LP-1 derivatives (|FC|>3)

Then, we analyzed the status of signalization pathways in LP-1 cells. Indeed, microarray data indicated that either signalization from transmembrane receptors (epithelial growth factor receptor (EGFR), tumor necrosis factor receptor (TNFR), hepatocyte growth factor receptor (HGFR), interleukin-21 receptor (IL-21R) etc.) or signalization molecules belonging to the phosphoinositol-3 kinase (PI3K)/AKT, Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3), mitogen-activated protein kinase (MAPK), nuclear factor (NF)-κB could be altered in LP-1 derived cells (Table (Table3).3). This was verified by immunoblotting (Figure (Figure4b).4b). The STAT3 pathway is constitutively activated in LP-1 cells. In LP-1K cells, this pathway is overactivated as shown by the hyperphosphorylation of STAT3 both in the cytoplasmic and nuclear compartments. The MAPK pathway is activated in LP-1K cells whereas the p70S6K pathway is activated in LP-1D1b cells. The AKT protein is downregulated in LP-1K cells. These data underline that, although structurally related, cyclin D1b and cyclin K are able to activate/inhibit different signaling pathways controlling survival and/or proliferation.

Table 3
Genes coding for signalization molecules displaying altered expression in LP-1 derivatives (|FC|>3)

The large number of genes and pathways altered by cyclin D1b and/or cyclin K expression precludes a thorough analysis in this manuscript. We focused on two discrete functions of cyclins D-type identified by the microarray analysis and well-known as support for tumorigenic process: cell migration and angiogenesis.

Cyclin K inhibits migration of LP-1-derived clones and enhances its clonogenic capacities

When observed with an inverted optical microscope, LP-1-derived clones exhibited different morphologies (Figure (Figure5a).5a). Compared to LP-1cl1 cells, LP-1D1b formed clusters of cells whereas LP-1K cells grew individually. At the transcriptional level, LP-1K but not LP-1D1b cells displayed major alterations of genes coding for attachment proteins such as integrins, lamin B, ADAMs, ICAMs, CD47 (Table (Table4).4). Explaining new morphological properties of the cells, we found that the gene ITGB7 coding for integrin β7, recognized as a major promoter of MM cell proliferation trough interactions with stroma cells [22] was downregulated in LP-1D1b cells and upregulated in LP-1K cells. LP-1K cells showed enhanced clonogenic capacities when plated in semi-solid medium compared to LP-1cl1 and LP-1D1b which showed similar capacities (Figure (Figure5b).5b). Cyclin D1 regulates cell proliferation and cell migration of mammary epithelial cells through the stabilization of p27Kip1 and its phosphorylation of a Ser10 residue [23]. We analyzed the level and the phosphorylated status of p27Kip1 in LP-1-derived cell clones (Figure (Figure5c).5c). Both the levels of p27Kip1 protein and its phosphorylated form were lower in LP-1D1b cells than in LP-1cl1 and p27Kip1 was no longer expressed in LP-1K cells both in the nuclear and cytoplasmic compartments. These results argue that cyclins D1b and K fail to stabilize p27Kip1. We next studied the migration properties of LP-1-derived clones by the Matrigel invasion assay. Compared to LP-1cl1 cells, LP-1D1b had a similar capacity to migrate whereas LP-1K cells had completely lost this migratory property (Figure (Figure5d5d).

Figure 5
Cyclin D1b- and cyclin K-expressing LP-1 cells display opposite clonogenic and migration properties. a) Exponentially growing cells were observed with an inverted phase contrast microscope and photographed. b) Clonogenic assay of LP-1-derived clones. ...
Table 4
Genes coding for molecules controlling adhesion and movement displaying altered expression in LP-1 derivatives (|FC|>3).

Cyclin D1b allows neo-angiogenesis of engrafted tumors

LP-1 cells such as myeloma cell lines synthesize angiogenic factors such as vascular endothelial growth factor (VEGF) (data not shown). Cyclin D1b and/or cyclin K expression in LP-1 cells impacted on proangiogenic and antiangiogenic gene expression (Table (Table5).5). Compared with LP-1K-, LP-1D1b-derived tumors were highly vascularized (Figure (Figure1b).1b). This was confirmed by IHC after labeling the CD34 antigen present on vessel endothelial cells. As observed in Figure Figure6a,6a, CD34 staining is detected mainly in LP-1D1b-derived tumors. The CAM assay was performed to evaluate the direct effect of cyclins D1b and K on tumor engraftment and tumor-mediated angiogenesis. Both cyclin D1b- and cyclin K-expressing LP-1 cells were able to generate tumors in the CAM model within few days. As shown in Figure Figure6b,6b, LP-1D1b cells gave rise to evolutive tumors characterized by higher volume and significantly greater vascularization than LP-1K cells. Tortuous capillaries are visible at the surface of LP-1D1b tumors while LP-1K tumors, characterized by lack of size progress, were not perfused. Thus, cyclin D1b promotes neoangiogenesis and consequently, tumor growth in vivo. To confirm the involvement of neoangiogenesis in tumorigenesis of LP-1D1b cells in xenografts, we injected either once VEGF siRNA (or the control scrambled siRNA) at the vicinity of the injection site or biweekly, chemical FGFR or VEGFR inhibitors, SSR and SAR respectively. As shown Figure Figure6c,6c, as expected, scrambled siRNA had no effects on tumor evolution. Administration of VEGF siRNA markedly diminished the volume of LP-1D1b-derived tumors for a 15 day-period. After 15 days, no more effects of VEGF siRNA were observed likely due to siRNA degradation and the tumor grew with a rate similar to the one of control. This is in agreement with the reported stability of siRNA in the delivery gel [24]. Importantly, SSR and SAR inhibitors completely abolished the growth of tumors indicating a role of FGFR and VEGFR in the tumor evolution. The capacity of VEGF siRNA as well as TK inhibitors to inhibit tumor growth strongly supports microarray and CAM data and the conclusion that cyclin D1b favors tumorigenesis through activation of a neoangiogenic process.

Table 5
Genes coding for proangiogenic or antiangiogenic molecules displaying altered expression in LP-1 derivatives (|FC|>3).
Figure 6
Cyclin D1b promotes tumor growth by stimulating angiogenesis. a) Fixed tumor sections were studied with conventional IHC for CD34 (brown staining) expression. Anti-CD34 Ab (MEC14.7) was purchased from Hycult Biotech. (Uden, The Netherlands). Images (40× ...

Discussion

Cyclin D1 is overexpressed in a broad range of solid malignancies, expressed in lymphoid tumors such as MM and MCL and not in their normal counterparts. However, in vivo studies failed to reveal a strong oncogenic potential of the conventional cyclin D1, referred to cyclin D1a [11,12]. By contrast, the cyclin D1 isoform b and the mutant cyclin D1 T286A are capable to transform cells in vitro [4-6] and to induce tumors in vivo [7,8]. These two forms of cyclin D1 share a strict nuclear localization suggesting that nuclear functions of cyclin D1 are necessary and/or sufficient for tumor formation. Mutations of the CCND1 gene disrupting the phosphorylation at Thr286 and thereby leading to nuclear accumulation of cyclin D1 have been described in endometrial and esophageal carcinomas further reinforcing this notion [25,26]. However, the molecular mechanisms of cyclin D1b-driven tumorigenesis are not fully elucidated. In cultured cells, cyclin D1b is not capable to activate its catalytic partner CDK4 and in turn, does not regulate positively the cell cycle [5,18], retains a strong transcriptional co-repressor activity, displays reduced binding to p27Kip1 and does not control cell migration [23]. Here we show that, in the context of MM cells, cyclin D1b confers a full malignant phenotype and allows cells engraftment in immune-compromised mice. The genome-wide analysis of LP-1D1b cells extends our understanding of the biological properties of cyclin D1b. Moreover, we have identified genes regulated by cyclin K, a viral oncogenic homolog of cyclin D1a and confirm the fundamental differences between the two cyclin D1 isoforms.

Cyclin D1b and cyclin K alter LP-1 cells metabolism

The tumorigenic properties of cyclins D1b and K are not conferred by an exacerbated proliferation. LP-1D1b and LP-1K cells display the same proliferation properties and cyclin D1b or cyclin K expressions have no major impact on cell cycle regulation. Conversely, genes involved in metabolism, signal transduction, transport, transcriptional and translational regulations are profoundly altered by cyclin D1b and/or cyclin K. In vivo, cyclin D1 inhibits oxidative glycolysis, lipogenesis, and mitochondrial gene activity in the mammary epithelium [27,28]. In both LP-1K and LP-1D1b cells, the gene transcription of LDHA (lactate dehydrogenase, FC: -4.37 and -10.78, respectively), GAPDH (glyceraldehyde-3-phosphate dehydrogenase, FC: -4.94 and -3.17, respectively) and ALDOA (aldolase A, FC: -2.69 and -3.73, respectively) is decreased. These enzymes catalyze important energy-yielding steps in carbohydrate metabolism. The expression of genes coding for key enzymes involved in oxidative glycolysis such as pyruvate kinase (PKM2, FC: -3.57), phosphoglycerate kinase 1 (PGK1, FC: -2.10), enolase 1 (ENO1, FC: -2.32) in LP-1D1b cells; enolase 2 (ENO2, FC: -2.82) in LP-1K cells are down-regulated. This suggests a reduction of glycolysis in tumor cells and, therefore, such as in mammary tumor cells, a paradoxical role of cyclin D1 [27]. Indeed, most of tumor cells show an enhanced glycolytic flux [29]. However, only fast growing tumor cells display markedly modified energy metabolism and multiple myeloma cells are considered as accumulating cells rather than proliferating cells.

Cyclin D1b and cyclin K modulate gene transcription and translation within LP-1 cells

The roles of cyclin D1 in regulating signal transduction, transcription and translation and their relevance in the cellular transformation process are documented [30]. Among the candidate effectors of cyclin D1 in cancer cells is the transcription factor C/EBPβ [31]. It has been shown, in breast cancer cells, that C/EBPβ is a constitutive repressor of cyclin D1 target genes and that cyclin D1 acts by antagonizing this repressor function. The disruption of signaling through C/EBPβ contributes to breast cell transformation. Interestingly, in LP-1D1b cells, we noticed the up-regulation of CEBPG (FC: +3.08), coding for a close related transcription factor C/EBPγ whose function in myeloma cells remains to be established. But it is tempting to speculate some functional redundancy between the two factors. Among the transcription factors altered by cyclin K and/or cyclin D1b expressions, besides MYC, MAF, ETS family members, well-known as major oncogenic actors in plasma cells [13], several others have been implicated in myeloma pathology such as ATF3/4, IRF4/8, NOTCH2, RUNX1/2, XBP1 through the modulation of genes controlling growth, survival and migration. All of them are altered in LP-1K and/or LP-1D1b cells (Table (Table6).6). In good correlation, survival and proliferation properties of LP-1K and LP-1D1b cells are modified compared with LP-1cl1 cells.

Table 6
Genes coding for transcription factors displaying altered expression in LP-1 derivatives.

Eukaryotic initiation factors (eIFs) control translation at the limiting step of initiation and several of them have been recognized as major actors in transformation processes [32]. In LP-1D1b cells, several genes coding for eIFs are upregulated (EIF4EBP1, FC: +3.35; EIF3EIP, FC: +2.79; EIF4A2, FC: +2.50; EIF3F, FC: +2.05; EIF1, FC: +2.02). By contrast, in LP-1K, EIF3A and EIF5 are downregulated (FC: -2.28 and -2.92, respectively). A more active translation likely explains the faster growth of LP-1D1b-derived tumors compared to LP-1K tumors.

Cyclin D1b and cyclin K have opposite action on LP-1 cells migration

Clinical observations indicate that cyclin D1 overexpression in human cancers correlate with metastasis. In cyclin D1-/- mouse embryonic fibroblasts, cyclins D1a and b have unique properties with regard to cell migration [33]. Cyclin D1a stabilizes p27Kip1 and inhibits RhoA-induced ROCK kinase activity promoting cell migration while cyclin D1b fails to stabilize p27Kip1 and has no effect on cell migration. Our results confirm that cyclin D1b does not affect LP-1 cells migration. Although cyclin K resembles cyclin D1a in agreement with its known biological functions: binding to CDK4/6, phosphorylation of pRb; one prominent feature of its structure is the impairment of p27Kip1 binding [34]. Accordingly, cyclin K expression in LP-1 is associated with the absence of p27Kip1, the lack of migration capacity and an enhanced clonogenic potential in vitro. Experiments assessing the metastatic potential of LP-1-derived cells in vivo are ongoing.

Cyclin D1b stimulates neoangiogenesis

Cyclin K/D1b-expressing cells, grafted onto the CAM of chicken embryo, generate within a few days tumors whose vascularization is significantly different. Tumors obtained in nude mice after s.c. injection of LP-1-derived cells show the same different vascularization. Indeed, LP-1 MM cells overexpressing cyclin D1b markedly promote tumor angiogenesis. Cyclin D1 regulates vascular endothelial growth factor (VEGF) production and thereby, growth of vascular endothelial cells and tumor [35]. The inhibition of tumor growth after local injection of VEGF siRNA confirmed a major role of VEGF in tumor expesnion. This result was further reinforced by the use of VEGFR inhibitors which could target either the MM tumoral cells or their immediate environment. Cyclins D1b and K induce transcriptional activation/inhibition of proangiogenic/antiangiogenic factors. One striking difference between the two cell lines is the overexpression of FGFR3 in LP-1D1b cells. Activation of the fibroblast growth factor 3 (FGFR3) expressed by myeloma cells and its ligand FGF present in the mouse could sustain in vivo angiogenesis such as in the bone marrow milieu [36]. The expression of 402 angiogenesis-associated genes has been studied in a large series of patients with a MM or a MGUS (monoclonal gammopathy of undetermined significance), considered as the premalignant state of MM, MM cell lines and their normal counterparts [37]. This study concluded that aberrant expression of proangiogenic and downregulation of antiangiogenic genes occur in all MM patients. Interestingly for our purpose, we noted that three genes were silent in MGUS and expressed in MM, namely IL6, FGF9 and FGFR3. It is tempting to speculate that the expression of FGFR3 triggers premalignant cells to enter a malignant state as observed in our model.

Cyclin D1b and cyclin K activate major actors of MM tumorigenesis

Besides CCND1, several genes have been recognized as major actors of MM tumorigenesis: CCND2, MAF, FGFR3, ITGB7 and CXCR3 [13]. All of them are altered in either LP-1D1b or LP-1K cells. This observation validates the use of LP-1-derived cells as a paradigm of tumorigenesis in MM. Moreover, based on previous microarray analyses, genes implicated specifically in the tumorigenic process of MM have been characterized [38-42]. Several of them are also detected in our microarray analysis. They code for proteins involved in metabolism, signal transduction, transcription factors and cell cycle regulators (Figure (Figure7).7). Among them only a few number of genes are recognized as tumorigenic in several MM models: BCL2, BNIP3, FGFR3, MCL1, RAN and XBP1. BCL2 protein is the archetype of apoptosis regulatory molecules; it is an integral outer mitochondrial membrane protein that blocks the apoptotic death. BCL2 is often overexpressed in transformed cells of the B lymphoid lineage, in malignant compared to normal plasma cells [39]. By contrast BNIP3 (BCL2/adenovirus E1B 19 kDa interacting protein 3) protein has pro-apoptotic function and BNIP3 gene is repressed in MM cells through the methylation of its promoter [42]. MCL1 encodes two proteins belonging to the BCL2 family with either pro- or antiapoptotic functions; its overexpression has been detected in blood sample from a myeloma patient but not in his twin [41]. The role of the transcription factor XPB1 and the nuclear protein RAN, a member of RAS family, in the myeloma pathogenesis remains to be defined. The t(4;14)(p16.3;q32) occurs in 15-20% of myeloma patients and leads to the overexpression of FGFR3 gene and, in turn, the constitutive activation of several signaling pathways in 80% of t(4;14)+ MM patients. Five genes (ATF3, BCKDHA, FGFR3, RRM2 and SDC1) are altered by cyclin D1b alone and six (BNIP3, CBS, CST3, HCLS1, RAN, SQSTM1) by both cyclins D1b and K. Those findings question the relevance of cyclin D1b expression in MM pathogenesis.

Figure 7
Schematic representation of genes involved in the pathogenesis of MM. We compared our microarray data with some previously published [37-41]. We then sorted genes characterized in our study and at least another one; genes cited in more than two studies ...

Is cyclin D1b involved in MM pathogenesis?

We have previously shown that both isoforms of cyclin D1a and b mRNAs are present in MM cells and their relative levels similar. However, cyclin D1a isoform is predominant both in MM cell lines and primary cells [16]. It has been thought that CCND1 alternative splicing was regulated by a G/A polymorphism at the exon 4/intron 4 boundary [1]. It is now demonstrated that factors associated with chromatin remodelling and translation elongation largely contribute to cyclin D1b accumulation [43,44]. This indicates that the regulation of cyclin D1b level is complex and only the direct analysis of the cyclin D1b protein could define its impact on disease. In a recent large multiethnic case-control study, Knudsen and his group showed that cyclin D1b is clearly elevated in a significant fraction of primary breast tumors but with a heterogeneous level within specimens and underexpressed in asynchronously proliferating cell lines [45,46]. They also show unambiguously that cyclin D1b levels are associated with adverse prognostic outcome. Such an analysis of cyclin D1b protein level in MGUS, the primary step of MM and primary MM cells should be conducted in order to definitely conclude on its role in MM pathogenesis.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

VM and J-MR performed in vivo experiments; VM performed Q-PCR and IHC assays, GT performed western blots, confocal microscopy and flow cytometry; J-ML and JW-B performed CAM assays; DD and BJ performed microarray analyses and validated statistically the results; GA made computational analyses; VM, J-MR, JW-B, DD and BJ critically revised the manuscript; BS designed experiments, analyzed and interpreted the data, drafted the manuscript. All authors approved the final version of the manuscript and its submission for publication.

Supplementary Material

Additional file 1:

Table S1. Sequences of primers used for validation of microarray data by Q-PCR.

Additional file 2:

Figure S1. Hierarchical clustering of cyclin K-altered genes. Clustering was visualized with TigrMev 4_03 software http://www.tm4.org/mev.html. Sequences with FC>3 were selected. Expression levels are shown for either upregulated genes (red) or downregulated genes (green). The name of probes is indicated in the treeview.

Additional file 3:

Figure S2. Hierarchical clustering of cyclin D1b-altered genes. See legend of Additional File 2.

Additional file 4:

Figure S3. Hierarchical clustering of cyclin K- and D1b-altered genes. See legend of Additional File 2.

Acknowledgements

We thank Anne Barbaras for excellent help with cell culture, Dr J. Cahu for careful reading of the manuscript, Dr D. Cappellen (Friedrich Miescher Institute, Basel, Switzerland) for the gift of c-Myc construct, Dr O. Coqueret, (INSERM U564, CLCC Paul Papin, Angers, France) for the gift of cyclin K construct, Dr F. Bono (Sanofi Aventis, Toulouse, France) for the gift of chemical inhibitors. This work was supported by grants from the Ligue contre le Cancer - Comité du Calvados and Comité de la Manche (to BS). GT received a scholarship form Ligue contre le Cancer - Comité du Calvados and from the Société Française d'Hématologie.

References

  • Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005–1011. [PubMed]
  • Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499–3511. doi: 10.1101/gad.12.22.3499. [PubMed] [Cross Ref]
  • Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000;15:3102–3114. doi: 10.1101/gad.854900. [PubMed] [Cross Ref]
  • Lu F, Gladden AB, Diehl JA. An alternative spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63:7056–7061. [PubMed]
  • Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES. Cyclin D1 splice variants. J Biol Chem. 2003;278:30339–30447. doi: 10.1074/jbc.M303969200. [PubMed] [Cross Ref]
  • Holley SL, Heighway J, Hoban PR. Induced expression of human CCND1 alternative transcripts in mouse Cyl-1 knockout fibroblasts highlights functional differences. Int J Cancer. 2005;114:364–370. doi: 10.1002/ijc.20750. [PubMed] [Cross Ref]
  • Lin DI, Lessie MD, Gladden AB, Bassing CH, Wagner KU, Diehl JA. Disruption of cyclin D1 nuclear export and proteolysis accelerates mammary carcinogenesis. Oncogene. 2008;27:1231–1242. doi: 10.1038/sj.onc.1210738. [PubMed] [Cross Ref]
  • Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene. 2006;25:998–1007. doi: 10.1038/sj.onc.1209147. [PMC free article] [PubMed] [Cross Ref]
  • Javiluoma A, Ojala PM. Cell signaling pathways engaged by KSHV. Biochim Biophys Acta. 2006;1766:140–158. [PubMed]
  • Verschuren EW, Hodgson JG, Gray JW, Kogan S, Jones N, Evan GI. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 2004;64:581–589. doi: 10.1158/0008-5472.CAN-03-1863. [PubMed] [Cross Ref]
  • Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13:2124–2130. [PubMed]
  • Lovec H, Grzeschiczek A, Kowalski MB, Möröy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487–3495. [PubMed]
  • Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333–6338. doi: 10.1200/JCO.2005.05.021. [PubMed] [Cross Ref]
  • Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7:750–762. doi: 10.1038/nrc2230. [PubMed] [Cross Ref]
  • Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasick MA. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase. Blood. 2006;108:1744–1750. doi: 10.1182/blood-2006-04-016634. [PubMed] [Cross Ref]
  • Krieger S, Gauduchon J, Roussel M, Troussard X, Sola B. Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer. 2006;6:238. doi: 10.1186/1471-2407-6-238. [PMC free article] [PubMed] [Cross Ref]
  • Lundquist A, Barré B, Bienvenu F, Hermann J, Avril S, Coqueret O. Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition. Blood. 2003;101:4070–4077. doi: 10.1182/blood-2002-07-1994. [PubMed] [Cross Ref]
  • Lévêque C, Marsaud V, Renoir JM, Sola B. Alternative cyclin D1 forms a and b have different biological functions in the cell cycle of B lymphocytes. Exp Cell Res. 2007;313:2719–2729. doi: 10.1016/j.yexcr.2007.04.018. [PubMed] [Cross Ref]
  • Le Brigand K, Russel R, Moreilhon C, Rouillard J-M, Jost B, Amiot F, Magnone V, Bole-Feysot C, Rostagno P, Virolle V, Defamie V, Dessen P, Williams G, Lyons P, Rios G, Mari B, Gulari E, Kastner P, Gidrol X, Freeman TC, Barbry P. An open-access long oligonucleotide microarray resource for analysis of the human and mouse transcriptomes. Nucleic Acids Research. 2006;34:e87. doi: 10.1093/nar/gkl485. [PMC free article] [PubMed] [Cross Ref]
  • Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289–300.
  • Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res. 2002;62:6884–6890. [PubMed]
  • Hurt EM, Wiestner A, Rosenwald A, Schaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow. Cancer Cell. 2004;5:191–199. doi: 10.1016/S1535-6108(04)00019-4. [PubMed] [Cross Ref]
  • Li Z, Jiao X, Wang C, Ju X, Lu Y, Yuan L, Lisanti MP, Katiyar S, Pestell RG. Cyclin D1 induction of cellular migration requires p27KIP1. Cancer Res. 2006;66:9986–9994. doi: 10.1158/0008-5472.CAN-06-1596. [PubMed] [Cross Ref]
  • Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004;64:3365–3370. doi: 10.1158/0008-5472.CAN-03-2682. [PubMed] [Cross Ref]
  • Moreno-Bueno G, Rodríguez-Perales S, Sánchez-Estévez C, Hardisson D, Sarrió D, Prat J, Cigudosa JG, Matias-Guiu X, Palacios J. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene. 2003;22:6115–6118. doi: 10.1038/sj.onc.1206868. [PubMed] [Cross Ref]
  • Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG, Klein PS, Rustgi A, Diehl JA. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene. 2006;25:6291–6303. doi: 10.1038/sj.onc.1209644. [PubMed] [Cross Ref]
  • Sakamaki T, Casimiro MC, Ju X, Quong AA, Katiyar S, Liu M, Jiao X, Li A, Zhang X, Lu Y, Wang C, Byers S, Nicholson R, Link T, Shemluck M, Yang J, Fricke ST, Novikoff PM, Papanikolaou A, Arnold A, Albanese C, Pestell R. Cyclin D1 determines mitochondrial function in vivo. Mol Cell Biol. 2006;26:5449–5469. doi: 10.1128/MCB.02074-05. [PMC free article] [PubMed] [Cross Ref]
  • Wang C, Li Z, Lu Y, Du R, Katiyar S, Yang J, Fu M, Leader JE, Quong A, Novikoff PM, Pestell RG. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc Natl Acad Sci USA. 2006;31:11567–11572. doi: 10.1073/pnas.0603363103. [PubMed] [Cross Ref]
  • Gogvadze V, Orreniius S, Zhivotovsky B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008;18:165–173. doi: 10.1016/j.tcb.2008.01.006. [PubMed] [Cross Ref]
  • Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Cyclin D1: normal and abnormal functions. Endocrinology. 2005;145:5439–5447. doi: 10.1210/en.2004-0959. [PubMed] [Cross Ref]
  • Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003;114:323–334. doi: 10.1016/S0092-8674(03)00570-1. [PubMed] [Cross Ref]
  • Gandin V, Miluzio A, Barbieri AM, Beugnet A, Kiyokawa H, Marchisio PC, Biffo S. Eukaryotic initiation factor is rate-limiting in translation, growth and transformation. Nature. 2008;455:684–688. doi: 10.1038/nature07267. [PMC free article] [PubMed] [Cross Ref]
  • Li Z, Wang C, Jiao X, Katiyar S, Casimiro MC, Prendergast GC, Powell MJ, Pestell RG. Alternate cyclin D1 mRNA splicing modulates P27KIP1 binding and cell migration. J Biol Chem. 2008;283:7007–7015. doi: 10.1074/jbc.M706992200. [PubMed] [Cross Ref]
  • Baek K, Brown RS, Birrane G, Ladias JA. Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9. J Mol Biol. 2007;366:563–573. doi: 10.1016/j.jmb.2006.11.057. [PMC free article] [PubMed] [Cross Ref]
  • Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, Weinstein IB, Monden M. Antisense to cyclin D1 inhibits vascular endothelial growth factor - stimulated growth of vascular endothelial cells: implication for tumor development. Clin Cancer Res. 2006;12:4720–4729. doi: 10.1158/1078-0432.CCR-05-1213. [PubMed] [Cross Ref]
  • Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–598. doi: 10.1038/nrc2189. [PubMed] [Cross Ref]
  • Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi J-F, Jauch A, Klein B, Möhler T. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114:128–143. doi: 10.1182/blood-2008-10-184226. [PubMed] [Cross Ref]
  • Claudio JO, Masih-Khan E, Tang H, Gonçalves J, Voralia M, Li ZH, Nadeem V, Cukerman E, Francisco-Pabalan O, Liew CC, Woodgett JR, Stewart AK. A molecular compendium of genes expressed in multiple myeloma. Blood. 2002;100:2175–2186. doi: 10.1182/blood-2002-01-0008. [PubMed] [Cross Ref]
  • De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, Pellet F, Pantesco V, Rème T, Jourdan M, Rossi JF, Ørntoft T, Klein B. Comparison of gene expression between malignant and normal plasma cells with oligonucleotide array. Oncogene. 2002;21:6848–6857. doi: 10.1038/sj.onc.1205868. [PubMed] [Cross Ref]
  • Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003;102:4505–4511. doi: 10.1182/blood-2003-01-0016. [PubMed] [Cross Ref]
  • Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004;103:1799–1806. doi: 10.1182/blood-2003-02-0402. [PubMed] [Cross Ref]
  • Heller G, Schmidt WM, Ziegler B, Holzer S, Müllauer L, Bilban M, Zielinski CC, Drach J, Zöchbauer-Müller S. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin in multiple myeloma cells. Cancer Res. 2008;68:44–54. doi: 10.1158/0008-5472.CAN-07-2531. [PubMed] [Cross Ref]
  • Batsche E, Yaniv M, Muchardt C. The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struct Mol Biol. 2006;13:22–29. doi: 10.1038/nsmb1030. [PubMed] [Cross Ref]
  • Sanchez G, Bittencourt D, Laud K, Barbier J, Delattre O, Auboeuf D, Dutertre M. Alteration of cyclin D1 transcript elongation by a mutated transcripion factor up-regulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci USA. 2008;105:6004–6009. doi: 10.1073/pnas.0710748105. [PubMed] [Cross Ref]
  • Wang Y, Dean JL, Millar EKA, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res. 2008;68:5628–5638. doi: 10.1158/0008-5472.CAN-07-3170. [PubMed] [Cross Ref]
  • Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Oncogene. 2009;28:1812–1820. doi: 10.1038/onc.2009.13. [PMC free article] [PubMed] [Cross Ref]

Articles from Molecular Cancer are provided here courtesy of BioMed Central